Source link : https://www.newshealth.biz/health-news/fda-oks-zolbetuximab-for-gastric-gastroesophageal-cancer/
The US Food and Drug Administration (FDA) has approved zolbetuximab (Vyloy, Astellas Pharma) in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma that is claudin 18.2 positive. FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. […]
Author : News Health
Publish date : 2024-10-18 19:41:55
Copyright for syndicated content belongs to the linked Source.